Literature DB >> 11940044

Growth hormone release after glucagon as a reliable test of growth hormone assessment in adults.

José Manuel Gómez1, Rosa María Espadero, Fernando Escobar-Jiménez, Federico Hawkins, Antonio Picó, José Luis Herrera-Pombo, Enric Vilardell, Alejandra Durán, Jordi Mesa, Eduardo Faure, Anna Sanmartí.   

Abstract

OBJECTIVE: To investigate the GH response to glucagon in adult patients with GH deficiency and in controls compared with the GH response to the insulin tolerance test (ITT) in patients with GH deficiency and to determine whether the use of glucagon results in a diagnostic utility test. PATIENTS AND
DESIGN: Seventy-three patients with adult GH deficiency and organic hypothalamic-pituitary disease were recruited, along with 46 controls. The patients were divided into five groups according to the number of associated hormone deficiencies present. MEASUREMENTS: Hypopituitary subjects underwent assessment of GH secretory status by the ITT, the glucagon test and measurement of serum IGF-I concentration. Controls underwent the glucagon test. After the ITT, glucose and GH levels were measured at baseline, 30, 60 and 90 minutes, and after glucagon at baseline, 90, 120, 150, 180, 210 and 240 minutes.
RESULTS: The highest GH value after the ITT in the patient group was 3 microg/l (0.76 +/- 0.82 microg/l), and after the glucagon test the highest GH peak value was 2.9 microg/l (0.64 +/- 0.79 microg/l). A correlation was found between the GH peak and the progressive number of hormone deficiencies. After the glucagon test, the GH peak obtained in the controls at 180 minutes was 9.8 +/- 4.6 microg/l and, on an individual basis, none of the 46 controls failed to achieve peak GH levels higher than 3 microg/l. In the controls, a negative correlation was observed between the GH response to glucagon and age (r = -0.389, P = 0.0075) and body mass index (r = -0.329, P = 0.0254). The accuracy of the glucagon test for differentiating patients from controls, estimated by receiver operating characteristics (ROC) curve methodology, showed that the cut-off of 3 microg/l for the GH peak provides 100% sensitivity and 100% specificity and is a reliable decision threshold.
CONCLUSIONS: The glucagon GH test is reliable and provides a clear separation between GH-deficient and normal adults. A single glucagon test with a cut-off of 3 microg/l for the GH peak is diagnostic of GH deficiency in adults and could be considered and studied as an alternative to the ITT.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11940044     DOI: 10.1046/j.1365-2265.2002.01472.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  31 in total

Review 1.  Diagnosis of adult growth hormone deficiency: still a matter of debate.

Authors:  F Camanni
Journal:  J Endocrinol Invest       Date:  2006-02       Impact factor: 4.256

2.  Growth hormone deficiency after mild combat-related traumatic brain injury.

Authors:  Adriana G Ioachimescu; Benjamin M Hampstead; Anna Moore; Elizabeth Burgess; Lawrence S Phillips
Journal:  Pituitary       Date:  2015-08       Impact factor: 4.107

3.  Clinical characteristics, timing of peak responses and safety aspects of two dosing regimens of the glucagon stimulation test in evaluating growth hormone and cortisol secretion in adults.

Authors:  Kevin C J Yuen; Beverly M K Biller; Laurence Katznelson; Sharon A Rhoads; Michelle H Gurel; Olivia Chu; Valentina Corazzini; Kellie Spiller; Murray B Gordon; Roberto Salvatori; David M Cook
Journal:  Pituitary       Date:  2013-06       Impact factor: 4.107

4.  Prevalence of pituitary hormone dysfunction, metabolic syndrome, and impaired quality of life in retired professional football players: a prospective study.

Authors:  Daniel F Kelly; Charlene Chaloner; Diana Evans; Amy Mathews; Pejman Cohan; Christina Wang; Ronald Swerdloff; Myung-Shin Sim; Jihey Lee; Mathew J Wright; Claudia Kernan; Garni Barkhoudarian; Kevin C J Yuen; Kevin Guskiewicz
Journal:  J Neurotrauma       Date:  2014-05-08       Impact factor: 5.269

5.  Low prevalence of growth hormone deficiency in Turkish patients with Hashimoto's thyroiditis.

Authors:  S Akin; K Aydin; Ö A Gürlek
Journal:  J Endocrinol Invest       Date:  2014-01-08       Impact factor: 4.256

Review 6.  Clinical and diagnostic approach to patients with hypopituitarism due to traumatic brain injury (TBI), subarachnoid hemorrhage (SAH), and ischemic stroke (IS).

Authors:  Ioannis Karamouzis; Loredana Pagano; Flavia Prodam; Chiara Mele; Marco Zavattaro; Arianna Busti; Paolo Marzullo; Gianluca Aimaretti
Journal:  Endocrine       Date:  2015-11-16       Impact factor: 3.633

7.  Glucagon stimulation test for the diagnosis of GH deficiency in adults.

Authors:  F L Conceição; A da Costa e Silva; A J Leal Costa; M Vaisman
Journal:  J Endocrinol Invest       Date:  2003-11       Impact factor: 4.256

8.  Growth hormone and cortisol secretion in the elderly evaluated using the glucagon stimulation test.

Authors:  Ana Beatriz Winter Tavares; Ignácio Antônio Seixas-da-Silva; Diego H S Silvestre; Maria Fernanda Castelar Pinheiro; Mario Vaisman; Flávia Lucia Conceição
Journal:  Endocrine       Date:  2017-03-11       Impact factor: 3.633

9.  Effects of gender, body weight, and blood glucose dynamics on the growth hormone response to the glucagon stimulation test in patients with pituitary disease.

Authors:  Jessica R Wilson; Andrea L Utz; Jessica K Devin
Journal:  Growth Horm IGF Res       Date:  2015-12-08       Impact factor: 2.372

Review 10.  Diagnosis of adult GH deficiency.

Authors:  V Gasco; G Corneli; S Rovere; C Croce; G Beccuti; A Mainolfi; S Grottoli; G Aimaretti; E Ghigo
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.